fda warning compounded semaglutide safety 2024 2025 National Hispanic Medical Association | After GLP-1 drugs were banned, counterfeit versions continued to circulate — and still do today. Understanding the risks and Hims and Hers warns investors

The GLP-1 market represents a significant business opportunity for digital health solutions that can support behavior change among individuals with obesity and diabetes

The companys website claims that this route of administration has better bioavailability and a quicker onset of action than traditional oral pills. It is unclear what scientific evidence these claims are based on

With seven additional phase 3 readouts expected in 2026, we believe retatrutide could become an important option for patients with significant weight-loss needs and certain complications, including knee osteoarthritis." Conclusion: A New Era in Obesity Treatment The TRIUMPH-4 results represent more than just incremental progressthey signal a paradigm shift in what's possible with pharmacological obesity treatment

Age and hormonal factors Metabolic rate declines naturally with age, and hormonal changes during perimenopause, menopause, and andropause compound the challenge